AU2014318924A1 - Atrasentan mandelate salts for the treatement of kidney diseases - Google Patents
Atrasentan mandelate salts for the treatement of kidney diseases Download PDFInfo
- Publication number
- AU2014318924A1 AU2014318924A1 AU2014318924A AU2014318924A AU2014318924A1 AU 2014318924 A1 AU2014318924 A1 AU 2014318924A1 AU 2014318924 A AU2014318924 A AU 2014318924A AU 2014318924 A AU2014318924 A AU 2014318924A AU 2014318924 A1 AU2014318924 A1 AU 2014318924A1
- Authority
- AU
- Australia
- Prior art keywords
- salt
- atrasentan
- mandelate
- mandelate salt
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877101P | 2013-09-12 | 2013-09-12 | |
| US61/877,101 | 2013-09-12 | ||
| US14/133,297 US8962675B1 (en) | 2013-09-12 | 2013-12-18 | Atrasentan mandelate salts |
| US14/133,297 | 2013-12-18 | ||
| PCT/US2014/054888 WO2015038571A1 (en) | 2013-09-12 | 2014-09-10 | Atrasentan mandelate salts for the treatement of kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014318924A1 true AU2014318924A1 (en) | 2016-03-17 |
Family
ID=52472936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014318924A Abandoned AU2014318924A1 (en) | 2013-09-12 | 2014-09-10 | Atrasentan mandelate salts for the treatement of kidney diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8962675B1 (enExample) |
| EP (2) | EP3044222B1 (enExample) |
| JP (1) | JP2016530311A (enExample) |
| CN (1) | CN105745204A (enExample) |
| AU (1) | AU2014318924A1 (enExample) |
| CA (1) | CA2923627C (enExample) |
| CL (1) | CL2016000583A1 (enExample) |
| MX (1) | MX2016003065A (enExample) |
| WO (1) | WO2015038571A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160221A1 (es) * | 2013-07-08 | 2016-05-22 | Abbvie Inc | Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan |
| CN105905245B (zh) * | 2016-06-03 | 2018-12-25 | 青岛北海船舶重工有限责任公司 | 用于水面无人艇布放回收的吊笼 |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| HRP20260121T1 (hr) | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
| PH12023550025A1 (en) | 2020-07-10 | 2024-03-11 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| AU2023366516A1 (en) | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU711832B2 (en) * | 1994-08-19 | 1999-10-21 | Abbvie Bahamas Ltd. | Endothelin antagonists |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US7208517B1 (en) * | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US6124341A (en) | 1996-02-13 | 2000-09-26 | Abbott Laboratories | Endothelin antagonists |
| US5801250A (en) | 1996-12-13 | 1998-09-01 | Abbott Laboratories | Process for the stereoselective production of nitro-enamine compounds |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2002524546A (ja) | 1998-09-14 | 2002-08-06 | アボット・ラボラトリーズ | 立体選択性ニトロ化合物の製造方法 |
| US20020055457A1 (en) | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| WO2002017912A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| US20030092757A1 (en) | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US20030022811A1 (en) | 2001-04-11 | 2003-01-30 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| UA79248C2 (en) * | 2001-11-09 | 2007-06-11 | Janssen Pharmaceutica Nv | Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| US20060189675A1 (en) | 2004-09-17 | 2006-08-24 | Steve King | Crystalline form of a drug |
| US20080132710A1 (en) | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| US20110086103A1 (en) * | 2008-04-04 | 2011-04-14 | Actavis Group Ptc Ehf | Novel mandelate salt of fesoterodine |
| US20100184026A1 (en) | 2009-01-22 | 2010-07-22 | Abbott Laboratories | Companion Diagnostic Assays For Endothelin Receptor Antagonists |
-
2013
- 2013-12-18 US US14/133,297 patent/US8962675B1/en active Active
-
2014
- 2014-09-10 CA CA2923627A patent/CA2923627C/en active Active
- 2014-09-10 JP JP2016542052A patent/JP2016530311A/ja active Pending
- 2014-09-10 AU AU2014318924A patent/AU2014318924A1/en not_active Abandoned
- 2014-09-10 WO PCT/US2014/054888 patent/WO2015038571A1/en not_active Ceased
- 2014-09-10 MX MX2016003065A patent/MX2016003065A/es unknown
- 2014-09-10 CN CN201480061886.9A patent/CN105745204A/zh active Pending
- 2014-09-10 EP EP14780663.2A patent/EP3044222B1/en not_active Not-in-force
- 2014-09-10 EP EP17172157.4A patent/EP3239148A1/en not_active Withdrawn
-
2015
- 2015-01-12 US US14/594,742 patent/US9637476B2/en active Active
-
2016
- 2016-03-11 CL CL2016000583A patent/CL2016000583A1/es unknown
-
2017
- 2017-03-21 US US15/464,455 patent/US20170190692A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9637476B2 (en) | 2017-05-02 |
| US20170190692A1 (en) | 2017-07-06 |
| US8962675B1 (en) | 2015-02-24 |
| EP3239148A1 (en) | 2017-11-01 |
| CA2923627C (en) | 2022-06-21 |
| US20150073031A1 (en) | 2015-03-12 |
| JP2016530311A (ja) | 2016-09-29 |
| EP3044222B1 (en) | 2017-07-05 |
| MX2016003065A (es) | 2016-05-26 |
| CN105745204A (zh) | 2016-07-06 |
| CL2016000583A1 (es) | 2016-11-11 |
| EP3044222A1 (en) | 2016-07-20 |
| CA2923627A1 (en) | 2015-03-19 |
| WO2015038571A1 (en) | 2015-03-19 |
| US20150126574A1 (en) | 2015-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170190692A1 (en) | Atrasentan mandelate salts | |
| CA2970192C (en) | Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof | |
| JP5315253B2 (ja) | ラセミ型イラプラゾールの固体形 | |
| KR101791724B1 (ko) | 결정질 날록솔-ｐｅｇ 접합체 | |
| EP4014976B1 (en) | Aprocitentan for use in the treatment of hypertension and related diseases in combination with valsartan | |
| CN106414416A (zh) | 结晶型ARB‑NEPi复合物及其制备方法和应用 | |
| EP3718602A1 (en) | Multicomponent crystal formulations | |
| JP2016511273A (ja) | Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型 | |
| JP2015120750A (ja) | ペミロラストの新しい結晶形 | |
| WO2019020706A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN | |
| WO2024169698A1 (en) | Crystalline forms or salts of a deuterated compound | |
| MX2015005910A (es) | Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar. | |
| TW201722950A (zh) | 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途 | |
| HK1226402A1 (en) | Atrasentan mandelate salts for the treatement of kidney diseases | |
| HK1226402B (en) | Atrasentan mandelate salts for the treatement of kidney diseases | |
| KR20160118358A (ko) | 이온 채널 조정제의 고체 형태 | |
| AU2017341020A2 (en) | Urea derivative | |
| JP7850336B1 (ja) | Ｌｐ（ａ）阻害剤化合物を含む経口組成物 | |
| HK40112768B (en) | Crystalline forms or salts of a deuterated compound | |
| HK40112768A (en) | Crystalline forms or salts of a deuterated compound | |
| WO2015106674A1 (zh) | 一种安塞曲匹的晶型及其制备方法、其药物组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |